Peer-reviewed veterinary case report
Medium-chain fatty acid octanoate helps failing dog hearts
By Gorgodze, Nikoloz et al.·Published in American journal of physiology. Heart and circulatory physiology·2026·Department of Cardiovascular Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The medium-chain fatty acid octanoate is a beneficial fuel for the failing heart.
- Species:
- dog
Plain-English summary
A group of dogs with heart failure were given a supplement called octanoate, a medium-chain fatty acid, to see if it could help their condition. After two weeks of heart pacing, which was causing their heart issues, the dogs receiving octanoate showed delayed progression of heart dysfunction and improved heart metabolism compared to those that did not receive the supplement. This suggests that octanoate could be a helpful treatment for dogs with heart failure, as it may protect heart function without needing complicated administration methods. Further studies are encouraged to explore this potential treatment for heart problems in pets.
Abstract
The failing heart displays marked alterations of energy substrate metabolism, with a reduced oxidation of long-chain fatty acids (FA) associated with increased glucose oxidation. Recent preclinical and human studies have shown that the delivery of ketone bodies as an alternative substrate reduces pathological cardiac remodeling and dysfunction in heart failure. However, chronic administration of ketone bodies is challenging. Therefore, using a clinically relevant canine model of tachypacing-induced dilated cardiomyopathy, we tested the hypothesis that other shorter-chain FA may also be beneficial. Seven dogs received cardiac tachypacing and continuous infusion of sodium octanoate, a medium-chain FA, starting after 2 wk of pacing when cardiac dysfunction was still moderate. Six dogs received cardiac pacing with no octanoate infusion. Octanoate did not significantly alter circulating levels of ketone bodies, whereas it still exerted protection, resulting in a delayed progression of systolic and diastolic cardiac dysfunction and normalized myocardial metabolism. These results identify the delivery of medium-chain FA as a potential actionable therapeutic for heart failure with reduced ejection fraction. Octanoate has translational promise due to proven methods of dietary supplementation with no need for parenteral administration.Provision of the medium-chain fatty acid octanoate prevented or reversed key metrics of cardiac functional and metabolic deterioration in a large animal model of dilated cardiomyopathy. Our results demonstrate the cardiac benefits of supplementing a medium-chain FA independent of ketosis in a translational model of heart failure. These findings encourage mechanistic and next-stage translational studies into metabolic interventions for the treatment of heart failure.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/42059887/